Rhythm Pharmaceuticals enters September with a familiar tension: short sellers are adding pressure while analysts who cover the stock remain broadly constructive — and the stock sits roughly 25% below the Street's average target.
Short interest has climbed meaningfully over the past month. It now represents 15.2% of the free float, up from around 14.1% a month ago and up 4.3% on the week. That is not a modest or incidental build — it is a deliberate, sustained increase across a period when the stock gained 5.5% on the month before giving back 7.6% in the past week. The short score of 65 has held broadly stable in a narrow band through late August, suggesting the bearish positioning is entrenched rather than reactive. Days to cover checks in at 12.2, meaning any forced unwind would take time.
The lending market, however, tells a very different story. Availability is anything but tight — it runs at roughly 1,500%, meaning roughly 15 times more shares are available to borrow than are currently borrowed. Cost to borrow is a nominal 0.47%, easing further from an already low level a month ago. There is no squeeze pressure in this setup. Shorts can add and exit freely. The put/call ratio has drifted slightly above its recent mean at 0.40, about 1.6 standard deviations above the 20-day average, but it remains well inside the past year's defensive extremes. Options traders have become a touch more cautious this week — the ratio was running closer to 0.35 through mid-August — but this is a modest shift, not a signal.
The Street is broadly bullish on RYTM, which makes the elevated short interest the central contradiction. Most recent analyst actions ran in the same direction: JPMorgan maintained Overweight and nudged its target to $146, Citigroup and Citizens both raised targets after the August 4 earnings print, and RBC Capital lifted its target sharply to $155 from $141. Deutsche Bank's David Hoang initiated last Thursday with a Hold and a $120 target — the lone dissenting voice, and the move that pulled the consensus rating down to Hold despite the weight of Buy-rated coverage. The mean price target of $140 implies roughly 34% upside from the current $104.74 close, a gap that the bears are clearly not persuaded by. The bear thesis centres on commercialisation execution risk for IMCIVREE (setmelanotide) and the possibility that competition from established obesity therapies constrains the addressable market before Rhythm can fully penetrate it. The bull case rests on a still-expanding rare-disease franchise, demonstrated BMI reductions in MC4R pathway patients, and promising Phase 2 data in Prader-Willi syndrome. Forward EPS estimates are trending sharply higher — the 12-month forward EPS growth factor scores in the 95th percentile of the universe — but the stock remains pre-profitable, carrying a price-to-book near 14x and a deeply negative PE and EV/EBITDA.
Institutional ownership offers some context on the divide. RA Capital Management holds nearly 10% of shares and added to its position as recently as February. Baker Bros. Advisors sits at 8.1%. Both are known specialist healthcare investors with long-horizon mandates — their stability in the register signals conviction in the pipeline rather than momentum trading. T. Rowe Price and JPMorgan Asset Management added material positions through July, the latter adding over a million shares. On the insider side, CFO Hunter C. Smith filed option exercises and open-market sales on August 31 under a pre-arranged 10b5-1 plan, resulting in net open-market sales of roughly $6.6 million across the 90-day window. All transactions were plan-driven — this is scheduled compensation management, not a discretionary signal.
The last earnings print provided some useful calibration. On August 4, the stock moved 7.7% higher on the day and extended that to 9.8% over the following week. The next event is November 3. Between now and then, the most relevant variable is the pace of IMCIVREE prescription growth and any updates on the PWS programme — the data point that could most directly shift the valuation argument in either direction.
See the live data behind this article on ORTEX.
Open RYTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
